EMA accepts marketing authorization applications of Mylan and Biocon for 2 biosimilars Ruby Khatun Khatun2 Dec 2017 10:00 AM ISTHERTFORDSHIRE, England, PITTSBURGH and BENGALURU: Mylan N.V. and Biocon Ltd. announced that the European Medicines Agency (EMA) has accepted for...
Biocon launches colon cancer drug in India, priced Rs 24,000 Ruby Khatun Khatun24 Nov 2017 10:01 AM ISTBengaluru: Biocon Ltd has launched KRABEVA, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and other types...
Roche sues Pfizer to bar biosimilar of cancer drug Herceptin Ruby Khatun Khatun22 Nov 2017 10:00 AM ISTRoche Holding AG, facing pressure in Europe as cheaper biosimilars of its three biggest cancer medicines chew away at its revenue, sued to block...
Intas Pharma cuts down price of cancer drug Bevacizumab by 60 percent Ruby Khatun Khatun6 Oct 2017 11:12 AM ISTAHMEDABAD: Intas Pharmaceuticals Limited, announced that the company is cutting down the cost of the cancer drug Bevacizumab by 60 percent in order to...
FDA rejects Coherus' biosimilar for Amgen's Neulasta Ruby Khatun Khatun13 Jun 2017 9:12 AM ISTn" style="transform: translate3d(0px, 0px, 0px);"Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration (FDA) denied the...